湖北宜化(000422) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥2,654,706,617.21, a decrease of 19.08% compared to the same period last year[9]. - The net profit attributable to shareholders was -¥189,141,626.34, representing a decline of 770.16% year-on-year[9]. - The company reported a net loss of CNY -2,690,006,517.16, compared to a loss of CNY -2,606,534,064.61 in the previous period[56]. - The total comprehensive loss for the current period was ¥216,547,510.50, compared to a comprehensive income of ¥5,551,470.07 in the previous period[66]. - The company’s total profit for the current period was a loss of ¥210,850,048.79, compared to a profit of ¥6,108,532.45 in the previous period[64]. Cash Flow - The net cash flow from operating activities decreased by 27.50% to ¥143,658,502.86 compared to the previous year[9]. - Cash inflows from operating activities were ¥2,602,230,373.04, down from ¥3,525,757,053.97 in the previous period, representing a decrease of approximately 26.1%[75]. - Cash outflow from operating activities totaled 2,458,571,870.18, down from 3,327,615,446.48, indicating a reduction of about 26.1%[78]. - Cash inflow from financing activities was 2,127,729,620.42, compared to 3,088,865,541.71 in the previous period, reflecting a decrease of approximately 30.9%[81]. - Cash and cash equivalents at the end of the period were 1,312,664,201.25, down from 2,488,034,961.47, a decrease of approximately 47.3%[81]. Assets and Liabilities - The total assets at the end of the reporting period were ¥22,685,697,484.46, down 1.90% from the end of the previous year[9]. - Total assets decreased to CNY 13,698,462,175.28 from CNY 14,314,583,215.47[56]. - The company's total liabilities decreased to ¥21,650,378,344.31 from ¥21,981,693,273.36, a decline of approximately 1.5%[46]. - Total liabilities decreased to CNY 13,528,488,612.27 from CNY 14,060,990,328.57[56]. Research and Development - The company's R&D expenses decreased by 36% compared to the same period last year due to reduced expenditures related to the pandemic[22]. - The company’s research and development expenses were CNY 63,154,097.77, compared to CNY 98,952,167.80 in the previous period[61]. - Research and development expenses for the current period were ¥22,808,528.07, a slight decrease from ¥23,318,145.32 in the previous period[68]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 49,562, with the largest shareholder holding 17.08%[12]. - The company reported no overdue commitments from major shareholders or related parties during the reporting period[25]. Inventory and Receivables - Accounts receivable increased to ¥377,637,867.90 from ¥171,720,562.21, reflecting a significant rise of approximately 119.9%[40]. - Inventory as of March 31, 2020, was ¥1,405,008,468.09, up from ¥1,372,708,745.29, indicating an increase of about 2.4%[40]. - Inventory decreased to CNY 177,323,898.92 from CNY 190,515,089.26[50]. Investment Activities - The company's investment income decreased by 65% year-on-year, mainly due to the previous year's transfer of shares in Leibo Huari[22]. - Net cash flow from investing activities was -67,375,386.96, worsening from -5,218,467.91, indicating a decline of approximately 1,192.5%[78]. - Cash outflow from investment activities was 73,671,120.96, compared to 104,111,445.68 in the previous period, showing a reduction of about 29.2%[78].